Application of circulating tumor DNA in endocrine therapy resistance of breast cancer / 国际肿瘤学杂志

ABSTRACT

Although most hormone-receptor positive breast cancer patients initially respond to endocrine treatment,they will eventually acquire resistance to endocrine therapy.Therefore,during clinical treatment,it is of great importance to continuously monitor for resistant mutations.Circulating tumor DNA (ctDNA) has become more prevalent because it is non-invasive,convenient,rapid,and can quickly assess the overall situation of the tumor.With the maturity of next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR),the establishment of endocrine treatment resistance mutation monitoring system has become possible.